CALYPSO BIOTECH
Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.
CALYPSO BIOTECH
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2013-01-01
Address:
Plan-les-ouates, Geneve, Switzerland
Country:
Switzerland
Website Url:
http://www.calypsobiotech.com
Total Employee:
11+
Status:
Active
Contact:
+41225523307
Total Funding:
30.5 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon WordPress Google Universal Analytics Font Awesome
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
NMD Pharma
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Current Advisors List
Board_member
2021-09-09
Board_member
Board_member
2017-11-01
Current Employees Featured
Alain Vicari CEO & Co-founder @ Calypso Biotech
CEO & Co-founder
Yolande Chvatchko CSO & Co-Founder @ Calypso Biotech
CSO & Co-Founder
Founder
Investors List
Fountain Healthcare Partners
Fountain Healthcare Partners investment in Series A - Calypso Biotech
M Ventures
M Ventures investment in Series A - Calypso Biotech
Johnson & Johnson Innovation
Johnson & Johnson Innovation investment in Series A - Calypso Biotech
Gilde Healthcare
Gilde Healthcare investment in Series A - Calypso Biotech
Inkef
Inkef investment in Series A - Calypso Biotech
Eclosion SA
Eclosion SA investment in Seed Round - Calypso Biotech
M Ventures
M Ventures investment in Seed Round - Calypso Biotech
Official Site Inspections
http://www.calypsobiotech.com
- Host name: ns8.medialook.net
- IP address: 51.255.79.159
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Calypso Biotech"
Calypso Biotech - Crunchbase Company Profile
Contact Email info@calypsobiotech.ch Phone Number +41225523307 Calypso Biotech is an innovative biopharmaceutical company based in Geneva, …See details»
Calypso Biotech SA - Plan-les-Ouates / Geneva, Switzerland
Jan 9, 2024 calypsobiotech.com. Contact. Profile Products News. Contact. About Calypso Biotech. Calypso is a private biotechnology company focused on the research and …See details»
Calypso Biotech SA – Swiss Biotech
Calypso Biotech, a clinical-stage spin-off from Merck Serono, develops therapeutic biologics that targets Interleukin-15 (IL-15). Its lead product is a best-in-class anti-IL-15 antibody CALY-002 …See details»
Calypso Biotech - Overview, News & Similar companies - ZoomInfo
Sep 9, 2021 View Calypso Biotech (www.calypsobiotech.com) location in Geneva, Switzerland , revenue, industry and description. Find related and similar companies as well as employees …See details»
Calypso Biotech - Craft
Calypso Biotech has 5 employees across 2 locations and $26.05 m in total funding,. See insights on Calypso Biotech including office locations, competitors, revenue, financials, executives, …See details»
Calypso Biotech BV - Drug pipelines, Patents, Clinical trials - Synapse
Www.calypsobiotech.com. Last update 23 Jan 2025. Overview. Pipeline. Deal. Translational Medicine. Profit. Grant & Funding(NIH) Investment. Financing. Overview. Tags. ... The …See details»
Calypso Biotech 2025 Company Profile: Valuation, Investors
Information on acquisition, funding, cap tables, investors, and executives for Calypso Biotech. Use the PitchBook Platform to explore the full profile.See details»
Calypso Biotech - Company Profile - Tracxn
Feb 21, 2025 Calypso Biotech - Developer of antibody-based therapeutics for the treatment of gastrointestinal diseases. Acquired by Novartis. Raised a total funding of $36.4M over 4 …See details»
Calypso Biotech SA - startup.ch
Calypso Biotech SA: Calypso Biotech SA, based in Geneva, Switzerland, is a biopharmaceutical company, spin-off from Merck Serono, focused on developing antibody therapies up to clinical …See details»
Calypso Biotech - VentureRadar
Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland, founded in 2013 as a spin-off Merck Serono. Its mission is... ... Find out ...See details»
Novartis’ Strategic Acquisition of Calypso: A Game-Changer in ...
Jan 10, 2024 Learn more about the company via its website www.calypsobiotech.com. About Novartis AG. Novartis AG, headquartered in Basel, Switzerland, stands as a formidable Swiss …See details»
AGC Biologics & Calypso Biotech BV Announce Manufacturing …
Feb 19, 2019 For more information on Calypso Biotech, please see https://www.calypsobiotech.com. About AGC Biologics AGC Biologics is a leading global …See details»
Calypso Biotech Completes CALY-002 Clinical Batch …
Jun 18, 2020 For more information on Calypso Biotech, please see www.calypsobiotech.com. About AGC Biologics: AGC Biologics is a leading global Contract Development and …See details»
Novartis Acquires Calypso Biotech for up to $425 Million
On Jan. 8, 2024, Calypso Biotech, a European immunotherapy biotech company focused on the research and development of novel biologics, announced it had agreed to be acquired by …See details»
Calypso Biotech Completes CALY-002 Clinical Batch Manufacturing
Jun 18, 2020 For more information on Calypso Biotech, please see www.calypsobiotech.com. About AGC Biologics: AGC Biologics is a leading global Contract Development and …See details»
Novartis to acquire Calypso Biotech for autoimmune treatment
Jan 8, 2024 The deal will give Novartis full rights to an antibody Calypso is working on to treat various autoimmune diseases. Calypso Biotech, a Dutch company developing treatments for …See details»
Gilde Healthcare announces Calypso to be acquired by Novartis …
Jan 8, 2024 The acquisition of Calypso gives Novartis full rights to CALY-002, a pipeline-in-a-drug with potential in dermatology, gastro-intestinal and rheumatology indications Calypso is a …See details»
Calypso Enters into Agreement to Be Acquired by Novartis
Jan 8, 2024 Calypso is a European biotech translating Interleukin-15 biology into medical breakthroughs by developing CALY-002, an anti-IL-15 monoclonal antibody, for an array of …See details»
Calypso Biotech Completes CALY-002 Clinical Batch Manufacturing
Jun 18, 2020 For more information on Calypso Biotech, please see www.calypsobiotech.com. About AGC Biologics: AGC Biologics is a leading global Contract Development and …See details»
Establishing Canada’s first large-scale bioinnovation centre
4 days ago The Neptune BioInnovation Centre (NBC), a 51,000 sq ft facility on a 12.3 acre lot in Dartmouth, will offer leasable wet and dry lab space, warehouse and office spaces, and …See details»